Apolipoprotein C-III, n-3 polyunsaturated fatty acids, and "insulin-resistant" T-455C APOC3 gene polymorphism in heart disease patients: Example of gene-diet interaction

Clinical Chemistry

Volumn 51, Issue 2, 2005, Pages 360-367

  Olivieri, Oliviero ^a,b   Martinelli, Nicola ^a   Sandri, Marco ^a   Bassi, Antonella ^a   Guarini, Patrizia ^a   Trabetti, Elisabetta ^a   Pizzolo, Francesca ^a   Girelli, Domenico ^a   Friso, Simonetta ^a   Pignatti, Pier Franco ^a   Corrocher, Roberto ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b POLICLINICO BORGO ROMA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; APOLIPOPROTEIN C3; APOLIPOPROTEIN E; CHOLESTEROL; CREATININE; DECOSAHEXAENOIC ACID; FIBRIC ACID DERIVATIVE; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICOSAPENTAENOIC ACID; INSULIN; LINOLEIC ACID; LINOLENIC ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OLEIC ACID; PALMITIC ACID; POLYUNSATURATED FATTY ACID; STEARIC ACID; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIET; DIETARY INTAKE; DISEASE PREDISPOSITION; DNA POLYMORPHISM; DNA RESPONSIVE ELEMENT; ERYTHROCYTE; FATTY ACID BLOOD LEVEL; FEMALE; GENE FREQUENCY; GENE INTERACTION; GENETIC ANALYSIS; GENETIC SUSCEPTIBILITY; HEART DISEASE; HOMOZYGOSITY; HUMAN; INSULIN RESISTANCE; LIPID BLOOD LEVEL; LIPID DIET; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE;

APOLIPOPROTEIN C-III; APOLIPOPROTEINS C; DIETARY FATS, UNSATURATED; FATTY ACIDS, OMEGA-3; FATTY ACIDS, UNSATURATED; FEMALE; HEART DISEASES; HUMANS; INSULIN RESISTANCE; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RESPONSE ELEMENTS; TRIGLYCERIDES;

EID: 19944433566     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2004.040477     Document Type: Article

References (29)

1. McConathy WJ, Gesquiere JC, Bass H, Tartar A, Fruchart JC, Wang CS. Inhibition of lipoprotein lipase activity by synthetic peptides of apolipoprotein C-III. J Lipid Res 1992;33:995-1003.
2. Ginsberg HN, Le NA, Goldberg IJ, Gibson JC, Rubinstein A, Wang-Iverson P, et al. Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo. J Clin Invest 1986;78:1287-95.
3. Blankenhorn DH, Alaupovic P, Wickham E, Chin HP, Azen SP. Prediction of angiographic change in native human coronary arteries and aortocoronary bypass grafts. Lipid and nonlipid factors. Circulation 1990;81:470-6.
4. Hodis HN, Mack WJ, Azen SP, Alaupovic P, Pogoda JM, LaBree L, et al. Triglyceride and cholesterol-rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin. Circulation 1994;90:42-9.
5. Mack WJ, Krauss RM, Hodis HN. Lipoprotein subclasses in the monitored atherosclerosis regression study (MARS). Treatment effects and relation to coronary angiographic progression. Arterioscler Thromb Vasc Biol 1996;16:697-704.
6. Luc G, Fievet C, Arveiler D, Evans AE, Bard JM, Cambien F, et al. Apolipoproteins C-III and E in apo B- and non-apo B-containing lipoproteins in two populations at contrasting risk for myocardial infarction: the ECTIM study. J Lipid Res 1996;37:508-17.
7. Thompson GR. Angiographic evidence for the role of triglyceride-rich lipoproteins in progression of coronary artery disease. Eur Heart J 1998;19:H31-6.
8. Sacks FM, Alaupovic P, Moye LA, Cole TG, Sussex B, Stampfer MJ, et al. VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the cholesterol and recurrent events (CARE) trial. Circulation 2000;102:1886-92.
9. Lee S-J, Campos H, Moye LA, Sacks FM. LDL particles containing apolipoprotein CIII are independent risk factors for coronary events in diabetic patients. Arterioscler Thromb Vasc Biol 2003;23:853-8.
10. Tilly P, Sass C, Vincent-Viry M, Aguillon D, Siest G, Visvikis S. Biological and genetic determinants of serum apo C-III concentration: reference limits from the Stanislas cohort. J Lipid Res 2003;44:430-6.
11. Dammerman M, Sandkuijl LA, Halaas JL, Chung W, Breslow JL. An apolipoprotein CIII haplotype protective against hypertriglyceridemia is specified by promoter and 3′ untranslated region polymorphisms. Proc Natl Acad Sci USA 1993;90:4562-6.
12. Li WW, Dammerman M, Smith JD, Metzger S, Breslow JL, Leff T. Common genetic variation in the promoter of the human apo CIII gene abolishes regulation by insulin and may contribute to hypertriglyceridemia. J Clin Invest 1995;96:2601-5.
13. Chen M, Breslow JL, Li W, Leff T. Transcriptional regulation of the apo C-III gene by insulin in diabetic mice: correlation with changes in plasma triglyceride levels. J Lipid Res 1994;35:1918-24.
14. Schoonjans K, Staels B, Auwerx J. Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J Lipid Res 1996;37:907-25.
15. Ye SQ, Kwiterovich PO Jr. Influence of genetic polymorphisms on responsiveness to dietary fat and cholesterol. Am J Clin Nutr 2000;72(Suppl):1275S-84S.
16. Olivieri O, Stranieri C, Bassi A, Zaia B, Girelli D, Pizzolo F, et al. Apolipoprotein CIII gene polymorphisms and risk of coronary artery disease. J Lipid Res 2002;43: 1450-7.
17. Olivieri O, Bassi A, Stranieri C, Trabetti E, Martinelli N, Pizzolo F, et al. Apolipoprotein CIII, metabolic syndrome and risk of coronary artery disease. J Lipid Res 2003;44:2374-81.
18. Arab L, Akbar J. Biomarkers and the measurement of fatty acids. Public Health Nutr 2002;5:865-71.
19. Koenker R, Bassett G. Regression quantiles. Econometrica 1978; 46:33-50.
20. Waterworth DM, Talmud P, Bujac SR, Fisher RM, Miller GJ, Humphries SE. Contribution of apolipoprotein C3 gene variants to determination of triglyceride levels and interaction with smoking in middle-aged men. Arterioscler Thromb Vasc Biol 2000;20: 2663-9.
21. Humphries SE, Talmud P, Cox C, Sutherland W, Mann J. Genetic factors affecting the consistency and magnitude of changes in plasma cholesterol in response to dietary challenge. QJM 1996; 89:671-80.
22. Lopez-Miranda J, Jansen S, Ordovas JM, Salas J, Marin C, Castro P, et al. Influence of the Sstl polymorphism at the apolipoprotein C-III gene locus on the plasma low-density-lipoprotein-cholesterol response to dietary monounsaturated fat. Am J Clin Nutr 1997;66:97-103.
23. Perez-Martinez P, Gomez P, Paz E, Marin C, Gavilan Moral E, Lopez-Miranda J, et al. Interaction between smoking and the Sstl polymorphism of the apo C-III gene determines plasma lipid response to diet. Nutr Metab Cardiovasc Dis 2001;11:237-43.
24. Brown S, Ordovas JM, Campos H. Interaction between the APOC3 gene promoter polymorphisms, saturated fat intake and plasma lipoproteins. Atherosclerosis 2003;170:307-13.
25. Dallongeville J, Baugé E, Tailleux A, Peters JM, Gonzalez FJ, Fruchart JC, et al. Peroxisome proliferator-activated receptor a is not rate-limiting for the lipoprotein-lowering action of fish oil. J Biol Chem 2001;276:4634-9.
26. Waterworth DM, Talmud PJ, Luan J, Flavell DM, Byrne CD, Humphries SE, et al. Variants in the APOC3 insulin responsive element modulate-insulin secretion and lipids in middle-aged men. Biochim Biophys Acta 2003;1637:200-6.
27. Kris-Etherton PM, Harris WS, Lawrence JA. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation 2002;106:2747-57.
28. Vidgren HM, Agren JJ, Schwab U, Rissanen T, Hanninen O, Uusitupa MI. Incorporation of n-3 fatty acids into plasma lipid fractions, and erythrocyte membranes and platelets during dietary supplementation with fish, fish oil, and docosahexaenoic acid-rich oil among healthy young men. Lipids 1997;32:697-705.
29. Katan MB, Deslypere JP, van Birgelen AP, Penders M, Zegwaard M. Kinetics of the incorporation of dietary fatty acids into serum cholesteryl esters, erythrocyte membranes, and adipose tissue: an 18-month controlled study. J Lipid Res 1997;38:2012-22.